GlassScriptPhysician profile
Phillip J States
NPI 1093791246
$4,405.27
in general payments reported to CMS, 2019-2025
35 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $691 · 2021: $953 · 2022: $1,130 · 2023: $576 · 2024: $357 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $754.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $607.31 | 2019-2024 | Xarelto |
| Abbvie INC. | $502.53 | 2019-2024 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $240.83 | 2019-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $230.40 | 2019-2023 | Gardasil 9, Vaxneuvance, Rotateq |
| E.R. Squibb & Sons, L.L.C. | $205.84 | 2019-2023 | Eliquis |
| Amgen INC. | $204.10 | 2020-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $198.01 | 2019-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Amarin Pharma, INC. | $159.61 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.73 | 2019-2024 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $140.07 | 2019-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $104.74 | 2020-2023 | Farxiga |
| Abbott Laboratories | $95.43 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $90.12 | 2019-2025 | |
| Dexcom, INC. | $85.20 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $79.12 | 2020-2022 | |
| Genentech USA, INC. | $63.50 | 2019-2021 | |
| Sanofi Pasteur INC. | $58.67 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.12 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $48.98 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $45.26 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $42.37 | 2024 | Rexulti |
| Shield Therapeutics INC | $34.96 | 2023-2024 | Accrufer |
| Alkermes, INC. | $26.06 | 2024 | Vivitrol |
| Allergan, INC. | $24.20 | 2020 | |
| Gilead Sciences, INC. | $23.92 | 2021 | |
| Inspire Medical Systems, INC. | $19.68 | 2024 | Inspire |
| Tactile Systems Technology INC | $18.47 | 2019 | |
| Irhythm Technologies, INC. | $18.44 | 2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.20 | 2021 | |
| Exeltis, USA INC. | $13.14 | 2024 | Slynd |
| Sanofi-Aventis U.S. LLC | $11.66 | 2019 | |
| Esperion Therapeutics, INC. | $11.39 | 2021 | |
| Biogen, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip States listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.